Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Evans, Mathew Wilkinson, Angeliki Giannpolou (2019)
Fast-Acting Insulin Aspart: The Rationale for a New Mealtime InsulinDiabetes Therapy, 10
J. Castle, J. Engle, J. Youssef, Ryan Massoud, W. Ward (2010)
Factors Influencing the Effectiveness of Glucagon for Preventing HypoglycemiaJournal of Diabetes Science and Technology, 4
D. Elleri, Janet Allen, K. Kumareswaran, L. Leelarathna, M. Nodale, K. Caldwell, P. Cheng, C. Kollman, A. Haidar, H. Murphy, M. Wilinska, C. Acerini, D. Dunger, R. Hovorka (2013)
Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 DiabetesDiabetes Care, 36
Available at https:// www.betabionics.org. Last accessed
W. BodeBruce, A. JohnsonJoseph, HyveledLiselotte, C. TamerSøren, DemissieMarek (2017)
Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.Diabetes Technology & Therapeutics, 19
K. Miller, N. Foster, R. Beck, R. Bergenstal, Stephanie DuBose, L. Dimeglio, D. Maahs, W. Tamborlane (2015)
Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic RegistryDiabetes Care, 38
A. Bon, Y. Luijf, Rob Koebrugge, R. Koops, Joost Hoekstra, J. DeVries (2014)
Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours.Diabetes technology & therapeutics, 16 3
K. Barnard, T. Wysocki, Vanessa Ully, J. Mader, T. Pieber, H. Thabit, M. Tauschmann, L. Leelarathna, S. Hartnell, C. Acerini, M. Wilinska, S. Dellweg, C. Benesch, S. Arnolds, M. Holzer, H. Kojzar, F. Campbell, J. Yong, Jennifer Pichierri, P. Hindmarsh, L. Heinemann, M. Evans, R. Hovorka (2017)
Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial SubstudyJournal of Diabetes Science and Technology, 11
H. Thabit, M. Tauschmann, Janet Allen, L. Leelarathna, S. Hartnell, M. Wilinska, C. Acerini, S. Dellweg, C. Benesch, L. Heinemann, J. Mader, M. Holzer, H. Kojzar, J. Exall, J. Yong, Jennifer Pichierri, K. Barnard, C. Kollman, P. Cheng, P. Hindmarsh, F. Campbell, S. Arnolds, T. Pieber, M. Evans, D. Dunger, R. Hovorka (2015)
Home Use of an Artificial Beta Cell in Type 1 Diabetes.The New England journal of medicine, 373 22
J. Cameron, A. Melrose (1962)
Changes in liver, pancreatic and stomach morphology following chronic glucagon administration in guinea-pigs.British journal of experimental pathology, 43
J. Castle, J. Youssef, P. Bakhtiani, Yu Cai, Jade Stobbe, D. Branigan, K. Ramsey, P. Jacobs, Ravi Reddy, M. Woods, W. Ward (2015)
Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop SystemDiabetes Care, 38
JT Ilkowitz, R Katikaneni, M Cantwell, N Ramchandani, RA Heptulla (2016)
Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed‐Loop System in Type 1 Diabetes: A Randomized Open‐Labeled Crossover Design Trial, 10
(2017)
BioChaperone Technology Enables rhGlucagon Aqueous Formulation for Use in Rescue and Dual-Hormone Artificial Pancreas (DHAP)
D. Russell-Jones, B. Bode, C. Block, E. Franek, S. Heller, C. Mathieu, A. Philis-Tsimikas, L. Rose, V. Woo, Anne Østerskov, Tina Graungaard, R. Bergenstal (2017)
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)Diabetes Care, 40
J. Youssef, J. Castle, P. Bakhtiani, A. Haidar, D. Branigan, Matthew Breen, W. Ward (2014)
Quantification of the Glycemic Response to Microdoses of Subcutaneous Glucagon at Varying Insulin LevelsDiabetes Care, 37
H. Galbo, J. Holst, N. Christensen (1975)
Glucagon and plasma catecholamine responses to graded and prolonged exercise in man.Journal of applied physiology, 38 1
(2017)
Dasiglucagon, a Novel Soluble Glucagon Analog, Successfully Restores Blood Glucose Levels after Hypoglycemia in People with Type 1 Diabetes Mellitus
A. Haidar, L. Legault, L. Matteau-Pelletier, V. Messier, M. Dallaire, M. Ladouceur, R. Rabasa‐Lhoret (2015)
Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.The lancet. Diabetes & endocrinology, 3 8
J. Sherr, E. Cengiz, C. Palerm, Bud Clark, N. Kurtz, Anirban Roy, L. Carria, Martin Cantwell, W. Tamborlane, S. Weinzimer (2013)
Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 DiabetesDiabetes Care, 36
(2017)
Mellitus ( T 1 DM )
Brett Newswanger, S. Ammons, N. Phadnis, W. Ward, J. Castle, R. Campbell, S. Prestrelski (2015)
Development of a Highly Stable, Nonaqueous Glucagon Formulation for Delivery via Infusion Pump SystemsJournal of Diabetes Science and Technology, 9
L. Ørskov, K. Alberti, A. Mengel, N. Møller, O. Pedersen, O. Rasmussen, T. Seefeldt, O. Schmitz (1991)
Decreased hepatic glucagon responses in Type 1 (insulin-dependent) diabetes mellitusDiabetologia, 34
A. Haidar, L. Legault, M. Dallaire, Ammar Alkhateeb, A. Coriati, V. Messier, P. Cheng, M. Millette, B. Boulet, R. Rabasa‐Lhoret (2013)
Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trialCanadian Medical Association Journal, 185
P. Herrero, M. El-Sharkawy, J. Daniels, N. Jugnee, Chukwuma Uduku, M. Reddy, N. Oliver, P. Georgiou (2019)
The Bio-inspired Artificial Pancreas for Type 1 Diabetes Control in the Home: System Architecture and Preliminary ResultsJournal of Diabetes Science and Technology, 13
Peter Jacobs, J. Youssef, Ravi Reddy, Navid Resalat, D. Branigan, John Condon, Nick Preiser, Katrina Ramsey, Madeleine Jones, Christopher Edwards, Kerry Kuehl, Joseph Leitschuh, U. Rajhbeharrysingh, J. Castle (2016)
Randomized trial of a dual‐hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor‐augmented pump therapyDiabetes, 18
A. Haidar, V. Messier, L. Legault, M. Ladouceur, R. Rabasa‐Lhoret (2017)
Outpatient 60‐hour day‐and‐night glucose control with dual‐hormone artificial pancreas, single‐hormone artificial pancreas, or sensor‐augmented pump therapy in adults with type 1 diabetes: An open‐label, randomised, crossover, controlled trialDiabetes, 19
M. Shichiri, Y. Yamasaki, R. Kawamori, N. Hakui, H. Abe (1982)
WEARABLE ARTIFICIAL ENDOCRINE PANCREAS WITH NEEDLE-TYPE GLUCOSE SENSORThe Lancet, 320
Giacomo Cappon, M. Vettoretti, G. Sparacino, A. Facchinetti (2019)
Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and ApplicationsDiabetes & Metabolism Journal, 43
S. Russell, F. El-Khatib, D. Nathan, E. Damiano (2010)
Efficacy Determinants of Subcutaneous Microdose Glucagon during Closed-Loop ControlJournal of Diabetes Science and Technology, 4
L. Sylow, M. Kleinert, E. Richter, T. Jensen (2017)
Exercise-stimulated glucose uptake — regulation and implications for glycaemic controlNature Reviews Endocrinology, 13
R. Gubitosi-Klug, B. Braffett, Neil White, R. Sherwin, F. Service, J. Lachin, W. Tamborlane (2017)
Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC StudyDiabetes Care, 40
A. Haidar, L. Legault, V. Messier, T. Mitre, C. Leroux, R. Rabasa‐Lhoret (2015)
Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.The lancet. Diabetes & endocrinology, 3 1
P. Jacobs, J. Youssef, J. Castle, P. Bakhtiani, D. Branigan, Matthew Breen, David Bauer, N. Preiser, Gerald Leonard, Tara Stonex, W. Ward (2014)
Automated Control of an Adaptive Bihormonal, Dual-Sensor Artificial Pancreas and Evaluation During Inpatient StudiesIEEE Transactions on Biomedical Engineering, 61
V. Gingras, Nadine Taleb, Amelie Roy-Fleming, L. Legault, R. Rabasa‐Lhoret (2018)
The challenges of achieving postprandial glucose control using closed‐loop systems in patients with type 1 diabetesDiabetes, 20
(2017)
The Novel Glucagon Receptor Agonist SAR438544, First in Human Safety, Pharmacokinetic, and Pharmacodynamic Data from a Study in Healthy Volunteers
J. Sherr, N. Patel, C. Michaud, M. Palau-Collazo, M. Name, W. Tamborlane, E. Cengiz, L. Carria, Eileen Tichy, S. Weinzimer (2016)
Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide, 39
H. Blauw, I. Wendl, J. deVries, T. Heise, T. Jax (2016)
Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levelsDiabetes, 18
M. Root (1956)
Effect of glucagon on glycogen in rats and rabbits.Endocrinology, 59 3
R. Davey, W. Howe, N. Paramalingam, L. Ferreira, E. Davis, P. Fournier, T. Jones (2013)
The effect of midday moderate-intensity exercise on postexercise hypoglycemia risk in individuals with type 1 diabetes.The Journal of clinical endocrinology and metabolism, 98 7
A. Haidar, M. Smaoui, L. Legault, R. Rabasa‐Lhoret (2016)
The role of glucagon in the artificial pancreas.The lancet. Diabetes & endocrinology, 4 6
A. Haidar, R. Rabasa‐Lhoret, L. Legault, L. Lovblom, Rohan Rakheja, V. Messier, Émilie D'Aoust, C. Falappa, Tara Justice, A. Orszag, Holly Tschirhart, M. Dallaire, M. Ladouceur, Bruce Perkins, Bruce Perkins (2016)
Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes.The Journal of clinical endocrinology and metabolism, 101 1
Ally MacDonald
Diabetes UKTrends in Urology & Men's Health, 2
A. Brazeau, R. Rabasa‐Lhoret, I. Strychar, H. Mircescu (2008)
Barriers to Physical Activity Among Patients With Type 1 DiabetesDiabetes Care, 31
R. Plotnikoff, L. Taylor, P. Wilson, K. Courneya, R. Sigal, N. Birkett, K. Raine, L. Svenson (2006)
Factors associated with physical activity in Canadian adults with diabetes.Medicine and science in sports and exercise, 38 8
E. Renard, A. Farret, J. Kropff, D. Bruttomesso, Mirko Messori, J. Place, Roberto Visentin, Roberta Calore, C. Toffanin, F. Palma, G. Lanzola, P. Magni, F. Boscari, S. Galasso, A. Avogaro, Patrick Keith-Hynes, B. Kovatchev, Simone Favero, C. Cobelli, L. Magni, J. DeVries (2016)
Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at HomeDiabetes Care, 39
A. Ranjan, S. Schmidt, S. Madsbad, J. Holst, K. Nørgaard (2016)
Effects of subcutaneous, low‐dose glucagon on insulin‐induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetesDiabetes, 18
M. Root (1954)
Effect of Chronic Administration of Glucagon to Rats and Rabbits.∗Proceedings of the Society for Experimental Biology and Medicine, 87
J. Castle, J. Engle, J. Youssef, Ryan Massoud, K. Yuen, R. Kagan, W. Ward (2010)
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 DiabetesDiabetes Care, 33
R. Bergenstal, S. Garg, S. Weinzimer, B. Buckingham, B. Bode, W. Tamborlane, F. Kaufman (2016)
Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes.JAMA, 316 13
P. Choudhary, M. Rickels, P. Senior, M. Vantyghem, P. Maffi, T. Kay, B. Keymeulen, N. Inagaki, F. Saudek, R. Lehmann, B. Hering (2015)
Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic HypoglycemiaDiabetes Care, 38
A. Weisman, Johnny-Wei Bai, Marina Cardinez, C. Kramer, B. Perkins (2017)
Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials.The lancet. Diabetes & endocrinology, 5 7
W. Tamborlane (2007)
Triple jeopardy: nocturnal hypoglycemia after exercise in the young with diabetes.The Journal of clinical endocrinology and metabolism, 92 3
Vanessa Moscardó, J. Díez, J. Bondia (2019)
Parallel Control of an Artificial Pancreas with Coordinated Insulin, Glucagon, and Rescue Carbohydrate Control ActionsJournal of Diabetes Science and Technology, 13
S. Weinzimer, J. Sherr, E. Cengiz, Grace Kim, Jessica Ruiz, L. Carria, Gayane Voskanyan, Anirban Roy, W. Tamborlane (2012)
Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 DiabetesDiabetes Care, 35
F. El-Khatib, S. Russell, D. Nathan, Robert Sutherlin, E. Damiano (2010)
A Bihormonal Closed-Loop Artificial Pancreas for Type 1 DiabetesScience Translational Medicine, 2
Philip Home (2012)
The pharmacokinetics and pharmacodynamics of rapid‐acting insulin analogues and their clinical consequencesDiabetes, 14
A. Bon, L. Jonker, Rob Koebrugge, R. Koops, J. Hoekstra, J. DeVries (2012)
Feasibility of a Bihormonal Closed-Loop System to Control Postexercise and Postprandial Glucose ExcursionsJournal of Diabetes Science and Technology, 6
S. McMahon, L. Ferreira, N. Ratnam, R. Davey, Leanne Youngs, E. Davis, P. Fournier, T. Jones (2007)
Glucose requirements to maintain euglycemia after moderate-intensity afternoon exercise in adolescents with type 1 diabetes are increased in a biphasic manner.The Journal of clinical endocrinology and metabolism, 92 3
Roderike Pohl, Ming Li, A. Krasner, Errol Souza (2014)
Development of Stable Liquid Glucagon Formulations for Use in Artificial PancreasJournal of Diabetes Science and Technology, 9
R. Bergenstal, D. Klonoff, S. Garg, B. Bode, M. Meredith, R. Slover, A. Ahmann, J. Welsh, Scott Lee, F. Kaufman (2013)
Threshold-based insulin-pump interruption for reduction of hypoglycemia.The New England journal of medicine, 369 3
(2017)
Preclinical Efficacy of a Stable Aqueous Formulation of Human Glucagon with BioChaperone Technology ( BC GLU )
A. Siafarikas, R. Johnston, M. Bulsara, P. O'Leary, T. Jones, E. Davis (2012)
Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 DiabetesDiabetes Care, 35
R. Heptulla, L. Rodriguez, L. Bomgaars, M. Haymond (2005)
The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.Diabetes, 54 4
J. Ilkowitz, R. Katikaneni, Martin Cantwell, Neesha Ramchandani, R. Heptulla (2016)
Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 DiabetesJournal of Diabetes Science and Technology, 10
R. Unger, A. Cherrington (2012)
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.The Journal of clinical investigation, 122 1
W. Ward, J. Castle, J. Youssef (2011)
Safe Glycemic Management during Closed-Loop Treatment of Type 1 Diabetes: The Role of Glucagon, Use of Multiple Sensors, and Compensation for Stress HyperglycemiaJournal of Diabetes Science and Technology, 5
Y. Lee, May-yun Wang, Xinxin Yu, R. Unger (2016)
Glucagon is the key factor in the development of diabetesDiabetologia, 59
Trang Ly, J. Nicholas, Adam Retterath, Ee Lim, E. Davis, T. Jones (2013)
Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial.JAMA, 310 12
J. Kropff, Simone Favero, J. Place, C. Toffanin, Roberto Visentin, Marco Monaro, Mirko Messori, F. Palma, G. Lanzola, A. Farret, F. Boscari, S. Galasso, P. Magni, A. Avogaro, Patrick Keith-Hynes, B. Kovatchev, D. Bruttomesso, C. Cobelli, J. DeVries, E. Renard, L. Magni (2015)
2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.The lancet. Diabetes & endocrinology, 3 12
Nadine Taleb, A. Haidar, V. Messier, V. Gingras, L. Legault, R. Rabasa‐Lhoret (2017)
Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic useDiabetes, 19
Nadine Taleb, A. Emami, C. Suppère, V. Messier, L. Legault, M. Ladouceur, J. Chiasson, A. Haidar, R. Rabasa‐Lhoret (2016)
Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trialDiabetologia, 59
M. MacDonald (1987)
Postexercise Late-Onset Hypoglycemia in Insulin-Dependent Diabetic PatientsDiabetes Care, 10
S. Russell, M. Hillard, C. Balliro, Kendra Magyar, R. Selagamsetty, M. Sinha, Kerry Grennan, Debbie Mondesir, L. Ekhlaspour, Hui Zheng, E. Damiano, F. El-Khatib (2016)
Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.The lancet. Diabetes & endocrinology, 4 3
S. Russell, F. El-Khatib, M. Sinha, Kendra Magyar, Katherine Mckeon, Laura Goergen, C. Balliro, M. Hillard, D. Nathan, E. Damiano (2014)
Outpatient glycemic control with a bionic pancreas in type 1 diabetes.The New England journal of medicine, 371 4
E. Iturralde, M. Tanenbaum, S. Hanes, Sakinah Suttiratana, Jodie Ambrosino, Trang Ly, D. Maahs, D. Naranjo, N. Walders-Abramson, S. Weinzimer, B. Buckingham, K. Hood (2017)
Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop SystemThe Diabetes Educator, 43
J. Castle, J. Youssef, D. Branigan, Brett Newswanger, P. Strange, M. Cummins, Leon Shi, S. Prestrelski (2016)
Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes SubjectsJournal of Diabetes Science and Technology, 10
F. El-Khatib, C. Balliro, M. Hillard, Kendra Magyar, L. Ekhlaspour, M. Sinha, Debbie Mondesir, Aryan Esmaeili, Celia Hartigan, M. Thompson, S. Malkani, J. Lock, D. Harlan, Paula Clinton, E. Frank, Darrell Wilson, D. DeSalvo, Lisa Norlander, Trang Ly, B. Buckingham, Jamie Diner, M. Dezube, L. Young, A. Goley, M. Kirkman, J. Buse, Hui Zheng, R. Selagamsetty, E. Damiano, S. Russell (2017)
Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trialThe Lancet, 389
What's new?We review the literature comparing the relative efficacy and utility of single‐ and dual‐hormone artificial pancreas systems.The pharmacokinetic profile of glucagon, with rapid onset and short duration of action, confers the major benefit of the dual‐hormone artificial pancreas.The dual‐hormone artificial pancreas is superior to single‐hormone systems in reducing hypoglycaemia overall and during exercise in short‐term studies, whereas there is no strong evidence of added benefit for preventing nocturnal or post‐exercise hypoglycaemia.The relative benefit of each system over the long term for improving HbA1c, preventing severe hypoglycaemia, and affecting quality of life remains unknown.IntroductionThe benefits of tight glycaemic control for reducing microvascular complications and all‐cause mortality in Type 1 diabetes must be balanced with the increased risk of hypoglycaemia and the elevated burden of diabetes self‐management that accompanies intensive glucose control. Moreover, fear of hypoglycaemia often leads to permissive hyperglycaemia, which is reflected in suboptimal HbA1c levels in people with Type 1 diabetes .With advances in technology, including continuous glucose monitoring and continuous subcutaneous insulin infusion (CSII) pumps (‘insulin pumps’), the burden of self‐monitoring capillary blood glucose and of multiple daily subcutaneous insulin injections is reduced. Recent evidence points to increased utilization of these emerging technologies, particularly among the
Diabetic Medicine – Wiley
Published: Jan 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.